Autism Spectrum Disorder Treatment Segmentation
Type (Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder)
The autistic disorders segment is predicted to hold 50% share of the global autism spectrum disorder treatment market by 2037. This is due to initiatives done by the government and industry participants, as well as factors like increased research and development. In addition to having an intellectual handicap, people with autism disorder typically experience severe language delays, social and communication difficulties, strange behaviours, and peculiar hobbies. The percentage of American children with autism has increased from 1 in 44 to 1 in 36. In the United States, 1 in 100 girls and 4 in 100 boys are autistic. In the United States, 1 in 100 girls and 4 in 100 boys are autistic. Compared to girls, boys have a nearly 4-fold higher diagnosis rate for autism.
Drug Class (Serotonin Uptake Inhibitors, Insomnia Drugs, Anticonvulsants, Antipsychotics)
Autism spectrum disorder treatment market from the antipsychotics segment is attributed to hold largest revenue share of about 40% during the forecast period. Antipsychotic medications are now widely available and are the safest and most successful treatment for individuals with autism, which explains this development. The only drugs currently licenced by the FDA to treat irritability in kids with autism spectrum conditions are Abilify and Risperdal. Patients with autism typically utilise these medications because of their superior safety, effectiveness, and tolerability compared to other medications.
Our in-depth analysis of the global autism spectrum disorder treatment market includes the following segments:
|
Type |
|
|
Drug Class |
|
|
Treatment Type |
|
|
Distribution Channel |
|
